Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: [email protected] www.cynata.com ASX ANNOUNCEMENT 8 October 2026 Termination of At-the-Market Subscription Deed Melbourne, Australia; 8 October 2026: Cynata Therapeutics...
Termination of At-the-Market Subscription Deed
Filed with ASX · · 1 page · English
Summary by 6ix AI
Cynata Therapeutics Limited has announced the termination of its At-the-Market Subscription Deed with Acuity Capital, effective from a specified date. The ATM previously provided Cynata with standby equity capital and involved the placement of shares as security. Following termination, the company intends to buy back and cancel the remaining shares held as security without any cash consideration. No termination fee or penalty is applicable to Cynata for this action.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Receives R&D TI Refund & Repays R&D TI Loan
- R&D Tax Incentive Loan Facility Extension
- Date of AGM and Closing Date for Director Nominations
- Appendix 4G
- Corporate Governance Statement
Later from Cynata Therapeutics
- Entitlement Offer & Unmarketable Parcel Sale Facility
- Proposed issue of securities - CYP
- Prospectus
- Target Market Determination
- Replacement Prospectus
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics